Launching a revolutionary liquid biopsy kit in turbulent times
Liquid biopsies offer minimally invasive, safe and convenient means of diagnosing cancer, making them useful for regular screening and increasing the chance of catching cancer in the early stages. With earlier detection comes an a higher likely hood that a cancer patient can receive curative treatment.
However, developing liquid biopsy kits can be challenging. Download this Leaflet to find out how Millipore Sigma helped Elypta to overcome these challenges and establish a liquid biopsy test for glycosaminoglycans that has progressed to clinical trials.
“Our mission at Elypta is to prevent cancer mortality through early detection by metabolism-based liquid biopsies. For a small company like ours, working with an organization like Merck to manufacture our diagnostic provides credibility for us, something that is very important, especially in the early stages.”
Karl Bergman, CEO, Elypta
This content was provided by Millipore Sigma.
Millipore Sigma is the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany
